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Background: Antimicrobials are the most common medicines prescribed to children, but very little is known
about patterns of hospital paediatric antimicrobial prescribing. This study aimed at describing paediatric anti-
microbial prescribing in European hospitals to identify targets for quality improvement.
Methods: The European Surveillance of Antibiotic Consumption (ESAC) project (www.esac.ua.ac.be) collected
data during 2 calendar weeks between May and June 2008 in 32 hospitals of 21 European countries with pae-
diatric departments, using a standardized method. The ESAC point prevalence survey included all inpatient beds
and identified all patients who were receiving systemic antimicrobials on the day of the survey or had received
antimicrobial surgical prophylaxis on the previous day.
Results: Of 1799 children, 583 (32%) received one or more antimicrobials (range 17%–100%). The indications
were therapeutic in 71%, prophylactic in 26% and both indications in 3% of patients. The parenteral route was
used in 82% of therapeutic indications and in 63% of prophylactic indications. Third-generation cephalosporins
were the most prescribed antimicrobials for therapeutic indications (18%). A high proportion of treated children
received antimicrobial combinations (37%). The most commonly treated diagnosis site was the respiratory
tract for both therapeutic use (30%) and prophylaxis (25%). The duration of surgical prophylaxis was .1
day in 67%.
Conclusions: Targets identified for quality improvement of antimicrobial use in children included excessive use
of antimicrobial combinations and a high proportion of parenteral antimicrobials, both of which require further
investigation. Surgical prophylaxis for .1 day should also be curbed in order to achieve quality improvement.
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Introduction
Antimicrobials are among the most commonly prescribed drugs
in both hospitals and the community. The link between antimi-
crobial use and the emergence of bacterial resistance has been
clearly established and represents a major public health
problem.1,2 The emergence of antibiotic resistance leads to
increases in length of stay, mortality and, subsequently, the
cost of healthcare.3 Several studies have reported on antimicro-
bial prescribing in hospitalized children,4 – 15 but there is no vali-
dated programme for monitoring antimicrobial prescribing in
children admitted to hospitals.16 This is predominantly because
the established surveillance programmes in hospitals have
focused on adults, even though children are very high users of
antimicrobials. The investigation of antimicrobial use in children
is crucial because they are an excellent environment for the
selection of resistant bacterial pathogens after recent antimicro-
bial use.17 In hospitals, the risk of the emergence and the trans-
mission of bacterial resistance are dramatically increased
because of the high incidence of patients treated with antimicro-
bials and close patient proximity.
Point prevalence surveys (PPSs) have been used to provide
information about nosocomial infections and antimicrobial
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use.4,9,10,12,13 Phase III of the European Surveillance of Antibiotic
Consumption (ESAC) project (www.esac.ua.ac.be), grant-funded
by the European Centre for Disease Prevention and Control
(ECDC), collects data on antimicrobial consumption in ambulat-
ory care and hospital settings from 34 European countries. The
ESAC Hospital Care Subproject developed a standardized
method for PPS (the ESAC PPS) on antimicrobial use in European
hospitals from different healthcare systems in 2006.18
The aims of this study were: (i) to describe antimicrobial
prescribing in paediatric units in 2008 at 32 hospitals from 21
European countries using the standardized ESAC PPS; (ii) to
assess the prescribed daily dose (PDD) in children; and (iii) to
identify targets for quality improvement of antimicrobial
prescribing in paediatric patients.
Methods
Data source and study population
Data were extracted from the 50 hospitals of the ESAC PPS 2008 data-
base. The ESAC national representatives were invited to recruit one or
several hospitals to participate in the ESAC PPS in 2008. In this report,
the analyses were restricted to hospitals with paediatric units: 32 hospi-
tals in 21 European countries (Austria, Belgium, Bulgaria, Switzerland,
Cyprus, Czech Republic, Estonia, France, Greece, Croatia, Hungary,
Ireland, Israel, Italia, Lithuania, Latvia, Malta, Portugal, Russia, Slovenia
and the UK).
Submission of data was done using a web-based application devel-
oped and validated by the ESAC project.18 This application allowed auto-
matic reporting for the participating hospitals. Additionally, a personal
digital assistant (PDA) could be used for data entry. The software for
the PDA was developed by the ESAC management team.
Data collection
The survey was carried out during a maximum of 2 calendar weeks
between 20 May and 30 June 2008 using a simplified version of the
2006 ESAC PPS protocol.18 Hospitals recruited clinical staff familiar with
reading patient notes (infection disease specialist, microbiologist,
pharmacist or infection control nurse) to perform the survey. The
survey could be completed by a single person or by a number of clinical
personnel.
All children who were present in the hospital at least 24 h before the
survey and present at 8 am on the day of the survey were included in the
survey. The following information was collected for children who were
receiving antimicrobials on the day of the survey: age; gender; and anti-
microbial agent according to the anatomical therapeutic chemical (ATC)
classification system19 (dose per administration, number of doses per day
and route of administration). Furthermore, the targeted anatomical site
according to a list of diagnosis groups and indication, including both
therapeutic use and prophylaxis, were also collected. For surgical
patients, administration of prophylactic antimicrobials in the previous
24 h was recorded, in order to code the duration of prophylaxis as: one
dose; 1 day; or more than 1 day.
Quantification of antimicrobial use
Antimicrobial prescriptions, including antibacterials for systemic use
(J01), antifungals (J02), rifampicin (J04AB02, excluding anti-tuberculosis
indication), oral vancomycin and colistin (A07AA09-10) and oral and
rectal metronidazole (P01AB01), were grouped at ATC level 4. Patients
who had received more than one antimicrobial were considered as
being on combination therapy. The mean PDD of individual antimicrobials
for the respective route of administration was calculated for the most fre-
quently used drugs. The PDD was defined as the observed dose received
by each patient. Due to the extremely large differences in dosing in pae-
diatrics, ranging from pre-term neonates to teenagers, the PDD was stra-
tified into five age groups (1, 0–11 months; 2, 12–23 months; 3, 2–4
years; 4, 5–9 years; 5, ≥10 years).
Data analysis
Data were analysed using SAS 9.1 (SAS Institute, Cary, NC, USA). The
results were analysed at the patient level. Separate analyses were
carried out for patients receiving therapeutic and prophylactic
antimicrobials.
Results
Antimicrobial overview
From the 32 ESAC PPS 2008 hospitals, there were a total of 69
paediatric units, of which 28 were medical, 26 were intensive
care and 15 were surgical wards. Of 1799 eligible children, 583
(32%) received one or more antimicrobial(s). The proportion of
patients receiving antibacterials ranged from 17% to 100% in
hospitals. The median age was 2 years, with 317 (54%) being
males. Medical wards included the highest proportion of all the
treated children, 316 (54%), followed by intensive care 172
(30%) and surgical wards 95 (16%). The average number of anti-
microbials per patient was higher in intensive care (mean 1.6;
range 1.0–2.3) than in medicine (mean 1.4; range 1.0–3.0) or
surgery (mean 1.4; range 1.0–2.0).
Of the 839 antimicrobials prescribed, antibacterials for sys-
temic use (J01) represented 96% of all prescriptions. Overall,
17 substances accounted for 75% of the total use (DU75%).
These included only two oral antibiotics (sulfamethoxazole and
trimethoprim, and amoxicillin and enzyme inhibitor). The indi-
cations for children receiving antimicrobials were therapeutic in
71% (n¼412), prophylaxis in 26% (n¼154) and both indications
in the remaining 3% (n¼17).
Prophylactic antimicrobial use
The parenteral route was more commonly used than the oral
route for prophylactic antimicrobials (parenteral, 63%; oral,
37%) (Table 1). Antimicrobial combinations represented 37% of
prophylaxis. The respiratory tract (25%) was the most common
site for prophylaxis. The completely undefined site represented
20% of overall prophylactics.
The pattern of antimicrobial use varied between surgical and
medical prophylaxis (Figure 1). Of the 171 prophylactic antimi-
crobials, 113 (66%) were prescribed for medical prophylaxis
and 58 (34%) for surgical prophylaxis.
For surgical prophylaxis, the duration was more than 1 day in
67% of children whilst single doses were used in 8%. Prophylaxis
was generally prolonged for more than 1 day for all sites. For
instance, it was longer than 1 day in all CNS and in 78% of
urinary tract prophylaxis cases. In surgical prophylaxis, combi-
nations of penicillins with b-lactamase inhibitors (J01CR) and
first-generation cephalosporins (J01DB) were the more
common drug classes (26% and 15%, respectively).
For medical prophylaxis, the top two classes were combi-
nations of sulphonamides and trimethoprim (J01EE) and ‘other
Amadeo et al.
2248
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/65/10/2247/707876 by U
niversity of M
alta user on 26 June 2019
aminoglycosides’ (J01GB) (referring to all aminoglycosides
with the exception of streptomycins; 22% and 20%, respect-
ively). However, ‘other aminoglycosides’ were often used in com-
bination with penicillins with extended spectrum (J01CA). This
dual therapy represented 17% of all medical prophylaxis.
Therapeutic antimicrobial use
The parenteral route was used in 82% of infections. The pro-
portion of antimicrobial combinations prescribed for infection rep-
resented 37% of all prescriptions and was similar to prophylaxis.
Respiratory tract infections (30%; Table 1), systemic infections
(16%) and ear, nose and throat infections (14%) accounted for
approximately 60% of all diagnoses for infections. The completely
undefined site represented only 4% of all diagnoses.
The top three antimicrobial classes were third-generation
cephalosporins (J01DD, 18%), ‘other aminoglycosides’ (J01GB,
14%) and penicillins with extended spectrum (J01CA, 10%)
(Figure 2). Of all antimicrobial combinations, ‘other aminoglyco-
sides’ and extended-spectrum penicillins (J01CA) was the most
common (n¼20, 13%). Children with respiratory tract infections
were most commonly treated with monotherapy using third-
generation cephalosporins (J01DD, 13%), macrolides (J01FA,
11%) or second-generation cephalosporins (J01DC, 11%).
Treatment of systemic infections included antimicrobial combi-
nations in 65% of cases, the most frequently used being the
combination of penicillins with either aminoglycosides (21%) or
cephalosporins (16%).
PDDs
The six most frequently used therapies were ampicillin, amoxicillin
and enzyme inhibitor, cefuroxime, ceftriaxone, sulfamethoxazole
and trimethoprim, and gentamicin. The PDD increased with age,
Table 1. Characteristics of patients receiving therapeutic and
prophylactic antimicrobials in paediatric units in 32 European hospitals
Characteristics
Therapeutic
use
Prophylactic
use
n % n %
Number of antimicrobials
1 antimicrobial 272 63.4 107 62.6
2–3 antimicrobials 148 34.5 59 34.5
.3 antimicrobials 9 2.1 5 2.9
Route of administration
oral 85 18.2 66 37.5
parenteral 383 81.8 110 62.5
Diagnosis
respiratory 127 29.6 42 24.6
systemica 67 15.6 13 7.6
ear, nose, throat 60 14.0 10 5.8
gastrointestinal 48 11.2 31 18.1
urology 41 9.6 16 9.4
skin, soft tissue, bone and joint 35 8.2 9 5.3
CNS 22 5.1 8 4.7
undefinedb 17 4.0 34 19.9
eye 6 1.4 1 0.6
central vascular system 5 1.2 5 2.9
gynaecology, obstetric 1 0.2 2 1.2
The total number of patients receiving antimicrobials was different for
each characteristic; a patient could receive both therapeutic and
prophylactic antimicrobials and both oral and parenteral antimicrobials.
aSystemic corresponds to bacteraemia (not endocarditis) and systemic
inflammatory response with no clear anatomical site.
bCompletely undefined site with no systemic inflammation.
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Other antimicrobials
Penicillins with extended spectrum (J01CA)
β-Lactamase-sensitive penicillins (J01CE)
Fluoroquinolones (J01MA)
Nitrofuran derivatives (J01XE)
Third-generation cephalosporins (J01DD)
Other aminoglycosides (J01GB)
Imidazole derivatives (J01XD + P01AB)
Second-generation cephalosporins (J01DC)
First-generation cephalosporins (J01DB)
Combinations of penicillins, including
β-lactamase inhibitors (J01CR)
5 10 15
Proportion of antimicrobial use (%)
Surgical prophylaxis
20 25 30 0
Other antimicrobials
Second-generation cephalosporins (J01DC)
Carbapenems (J01DH)
Triazole derivatives (J02AC)
Glycopeptide antibacterials (J01XA)
β-Lactamase-sensitive penicillins (J01CE)
Third-generation cephalosporins (J01DD)
Combinations of penicillins, including
β-lactamase inhibitors (J01CR)
Penicillins with extended spectrum (J01CA)
Other aminoglycosides (J01GB)
Combinations of sulphonamides and
trimethoprim, including derivatives (J01EE)
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Medical prophylaxis
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Figure 1. Proportion of antimicrobial prophylactic use in paediatric units for the 10 most frequently used groups at ATC level 4.
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as shown in Table 2, with a ratio (oldest children/youngest chil-
dren) ranging from 5-fold for ceftriaxone to 21-fold for gentamicin.
Discussion
Approximately one-third of paediatric patients were on antimi-
crobials, with considerable differences between hospitals. These
variations could be explained by the characteristics of hospital
care systems, which differ across countries, and by the case
mix.20 Hospitals with similar patient populations could have
different prescribing patterns, influenced by local antibiograms
and formularies. Therefore, data are intended for auditing
trends of use within the same institution, not for benchmarking
between hospitals.
Several targets for quality improvement were identified. The
first performance indicator was the high proportion of parenteral
antimicrobials, especially for therapeutic indications, since this is
associated with vascular line infections, inconvenience to
patients, prolonged hospital stay and increased costs.21 A
number of factors partially explain this high rate of parenteral
use. These include: life-threatening infections (e.g. systemic
infections and CNS infections) requiring intravenous therapy;
drugs available exclusively for parenteral use (e.g. the aminogly-
cosides, one of the most used classes); and the fact that neo-
nates and younger infants are unable to take oral medications.
Although a number of factors could partially explain this high
rate of parenteral use, individual hospitals should develop effec-
tive strategies to use oral instead of parenteral antimicrobials
whenever possible (e.g. after the critical phase of infection is
over switching to oral therapy has become the mainstay of
antibiotic therapy for the majority of patients).22
The second performance indicator identified was the high pro-
portion of antimicrobial combinations. Several reasons could be
advanced to justify the use of antimicrobial combinations,
including: prevention of the emergence of resistant organisms
(e.g. efficacy of combinations to prevent mutational resistance
in the treatment of tuberculosis); polymicrobial infections (e.g.
intraperitoneal and pelvic infection caused by mixed aerobic
and anaerobic organisms); initial therapy; and synergism.23
Despite this, there is clear evidence to prefer monotherapy
because combination therapy may have important negative
effects, such as drug interactions, increased cost and adverse
effects. In our study, the appropriate use of antimicrobial
combinations was not assessed. However, an example of
misuse was the number and type of antimicrobial combinations
used in surgical prophylaxis (24%). Most frequently this included
an overlap of anti-anaerobic cover with metronidazole added
to a penicillin with enzyme inhibitor. Analysing the type of
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Other antimicrobials
β-Lactamase-resistant penicillins (J01CF)
Carbapenems (J01DH)
Macrolides (J01FA)
Glycopeptide antibacterials (J01XA)
β-Lactamase-sensitive penicillins (J01CE)
Second-generation cephalosporins (J01DC)
Combinations of penicillins, including
β-lactamase inhibitors (J01CR)
Penicillins with extended spectrum (J01CA)
Other aminoglycosides (J01GB)
Third-generation cephalosporins (J01DD)
5 10 15
Proportion of antimicrobial use (%)
20 25 30
Figure 2. Proportion of antimicrobial therapeutic use in paediatric units
for the 10 most frequently used groups at ATC level 4.
Table 2. Distribution of PDDs for the six most frequently used antimicrobials in paediatric units stratified by age
Antimicrobials
Number of
therapies DDD (g)
PDD (g), median (IQR)
0–11 months 12–23 months 2–4 years 5–9 years ≥10 years
Gentamicin (P) 76 0.24 0.01 (0.01–0.03) 0.07 (0.06–0.07) 0.07 (0.06–0.09) 0.15 (0.15–0.22) 0.21 (0.16–0.24)
Ceftriaxone (P) 59 2 0.40 (0.23–0.50) 0.75 (0.56–1.00) 1.00 (0.90–1.00) 1.45 (1.00–1.50) 2.00 (2.00–3.00)
Ampicillin (P) 54 2 0.34 (0.20–0.45) 0.54 (0.36–0.96) 1.00 (0.60–1.00) 2.90 (2.60–3.20) 4.00a
Cefuroxime (P) 52 3 0.44 (0.18–0.55) 1.50 (1.20–1.50) 0.80 (0.75–0.84) 2.00 (1.50–3.90) 2.25 (1.50–4.25)
Sulfamethoxazole and
trimethoprim (O)
46 1.92 0.15 (0.14–0.24) 0.24 (0.15–0.24) 0.48 (0.24–0.48) 0.25 (0.10–0.48) 0.96 (0.24–1.72)
Amoxicillin and
enzyme inhibitor (P)
43 3 0.33 (0.20–0.66) 0.80 (0.60–0.90) 1.20 (1.20–2.36) 2.60 (1.82–3.00) 3.60 (3.00–3.60)
Amoxicillin and
enzyme inhibitor (O)
23 1 0.23 (0.15–0.26) 0.38 (0.28–0.47) 0.99 (0.19–1.37) 1.00 (0.90–1.35) 1.75 (1.05–1.80)
Route of administration: P, parenteral; O, oral.
The interquartile range (IQR) corresponds to the 25th percentile and the 75th percentile. Therefore, half of the distribution is between these
percentiles.
The DDD (defined daily dose) is a standardized unit defined by the WHO for the main indication in an adult of 70 kg.
aSample size too small to give the percentiles.
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combinations used for infections, nearly a quarter of the combi-
nation therapies included what seemed to be non-clinically rel-
evant combinations (e.g. penicillin with extended spectrum
plus a third-generation cephalosporin).
The third performance indicator identified was a duration
of surgical prophylaxis of more than 24 h. While prolonged anti-
biotic prophylaxis showed no improvement in preventing the risk
of infection, the ecological risk is pertinent.24 A previous study
performed in France in children and adults using the ESAC PPS
showed that 50% of antimicrobial prophylaxis was not in line
with local guidelines.25 Similarly, a recent multicentre survey in
four tertiary neonatal intensive care units in the USA showed
frequent inappropriately prolonged post-surgical use of anti-
microbials (.48 h).14 These data show that even in the most
documented evidence-based area of practice, which recom-
mends a surgical antimicrobial prophylaxis duration of less
than 24 h, clinicians tend to overprescribe, and this is a global
phenomenon not exclusive to Europe.
In this study it was confirmed that the PDD increased with
age and weight. Thus, further studies focusing on antimicrobial
use in children could define standardized paediatric daily doses
for different paediatric age groups and neonates separately.
This study found that, for children ≥10 years old, the PDD for
four antimicrobials was similar to or higher than the defined
daily dose (DDD). These results add to the evidence from other
studies that the DDD does not correspond to the PDD for many
classes of antimicrobials in adults.26,27
Finally, it is important to highlight the fact that the sample
size may not be representative of European paediatric units.
Nevertheless, surveillance of antimicrobial use at the hospital
level is the first step in auditing, identifying and improving on
the current situation with respect to inappropriate prescribing.
The ESAC PPS offers a standardized instrument that can ident-
ify targets for quality improvement of antimicrobial use in chil-
dren. The use of the ESAC PPS in a larger sample of paediatric
units in Europe could help to define standardized units for anti-
microbial prescription in the different age groups in children.28
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